News – Page 652 – Endpoints News

A new way to infiltrate (and destroy) some of the deadliest drug-resistant bugs

4 years ago

Former Shkreli company Travere lands licensing deal with Vifor on kidney drug

4 years ago

The Ariad vets developing next-gen TKIs are heading back to Nasdaq — and OrbiMed stands to reap the most

4 years ago

Endocrine-focused biotech gets new cash for its peptides, with dreams of launching a franchise

4 years ago

Takeda scores a win for a rare type of lung cancer, gearing up for a showdown with J&J

4 years ago

Who needs primary endpoints anyway? Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease

4 years ago

Zymeworks squares up with Herceptin after HER2 bispecific aces mid-stage test in esophageal cancer

4 years ago

Amgen rolls out data for KRAS inhibitor combo study in colorectal cancer, hoping to move on from ugly early results

4 years ago

Acepodia uncorks a very early win for its antibody-natural killer cell conjugates in HER2 tumors

4 years ago

Pfizer backs a small Swiss upstart's attempt to discover a non-viral gene therapy

4 years ago

Attempting to ride booster adcomm coattails, Moderna says its Covid-19 shot is better than Pfizer/BioNTech

4 years ago

FDA appears unconvinced by Pfizer's case for Covid-19 booster in lead up to adcomm

4 years ago

FDA clears first-of-its-kind trial to see if CRISPR gene editing can cure HIV

4 years ago

Three Democrat reps oppose Medicare drug pricing plan; Alpine Immune announces private placement

4 years ago

Not so fast: FDA tacks 3 more months onto decision date for Calliditas' rare kidney disorder drug

4 years ago

Three more biotechs hit Nasdaq as the sector, now with more than $13B raised, continues barreling toward record

4 years ago

Looking for the next mRNA breakthrough, Moderna taps AbCellera in mysterious antibody discovery deal

4 years ago

Once held back, Amylyx execs say the FDA is now pushing for an NDA on ALS drug

4 years ago

Back-to-back pivotal failures force Theravance to lay off 270 staffers, prune R&D focus

4 years ago

Boston, the Bay Area and San Diego dominate the life sciences real estate market. Where to next?

4 years ago

Pain player Allay makes good on launch promises, locking down latest fundraising round to advance lead implant

4 years ago

Surging US demand triggers new $2.9B purchase of Regeneron's Covid-19 antibodies

4 years ago

Covid-19 roundup: Gilead touts preclinical promise for oral remdesivir; Roche prepares for virus to become endemic

4 years ago

Five months after getting slapped with a clinical hold, KalVista gets the OK to restart oral HAE program

4 years ago

First page Previous page 649 650 651652653 654 655 Next page Last page